As on Wednesday, Lineage Cell Therapeutics Inc (AMEX: LCTX) got off with the flyer as it spiked 9.53% to $0.93, before settling in for the price of $0.84 at the close. Taking a more long-term approach, LCTX posted a 52-week range of $0.77-$1.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 119.78%. Meanwhile, its Annual Earning per share during the time was 19.25%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -23.61%. This publicly-traded company’s shares outstanding now amounts to $188.84 million, simultaneously with a float of $188.00 million. The organization now has a market capitalization sitting at $174.67 million. At the time of writing, stock’s 50-day Moving Average stood at $0.8801, while the 200-day Moving Average is $1.0223.
Lineage Cell Therapeutics Inc (LCTX) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Lineage Cell Therapeutics Inc’s current insider ownership accounts for 0.44%, in contrast to 50.65% institutional ownership. According to the most recent insider trade that took place on Aug 16 ’24, this organization’s Chief Financial Officer bought 10,500 shares at the rate of 0.89, making the entire transaction reach 9,345 in total value, affecting insider ownership by 10,500. Preceding that transaction, on May 24 ’24, Company’s President and CEO bought 10,000 for 1.05, making the whole transaction’s value amount to 10,500. This particular insider is now the holder of 154,842 in total.
Lineage Cell Therapeutics Inc (LCTX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
Lineage Cell Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -23.61% and is forecasted to reach -0.14 in the upcoming year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Let’s observe the current performance indicators for Lineage Cell Therapeutics Inc (LCTX). It’s Quick Ratio in the last reported quarter now stands at 2.64. The Stock has managed to achieve an average true range (ATR) of 0.05. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 28.22.
In the same vein, LCTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.13, a figure that is expected to reach -0.04 in the next quarter, and analysts are predicting that it will be -0.14 at the market close of one year from today.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Through scrutinizing the latest numbers posted by the [Lineage Cell Therapeutics Inc, LCTX], it can be observed that its last 5-days Average volume of 0.51 million was lower the volume of 0.78 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 55.18% While, its Average True Range was 0.0458.
Raw Stochastic average of Lineage Cell Therapeutics Inc (LCTX) in the period of the previous 100 days is set at 41.33%, which indicates a major fall in contrast to 88.46% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 63.31% that was higher than 61.45% volatility it exhibited in the past 100-days period.
